Evidence map›Paper›PMID 39741992›Full record

ArticleGlobal health & medicine2024

Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection.

Miyako M Chikanishi, Junko Tanuma, Kenji Ishii, Muneyuki Sakata, Noritoshi Arai, Tomoyuki Noguchi, Kensuke Komatsu, Kimiteru Ito, Tetsuya Mizoue, Kazuo Kubota and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Miyako M ChikanishiDepartment of Neuroradiology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.
Junko TanumaDepartment of AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kenji IshiiResearch Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Muneyuki SakataResearch Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Noritoshi AraiDepartment of Neurology, National Center for Global Health and Medicine, Tokyo, Japan.
Tomoyuki NoguchiDepartment of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Kensuke KomatsuDepartment of AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kimiteru ItoDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, National Center for Global Health and Medicine, Tokyo, Japan.
Kazuo KubotaDepartment of Radiology, Southern Tohoku General Hospital, Fukushima, Japan.
Takeyuki WatadaniDepartment of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroyuki GatanagaDepartment of AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinichi OkaDepartment of AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.

Indexed as

cARTFDGHIV associated neurocognitive disorder (HAND)PETVBM

Identifiers

PMID39741992
PMCPMC11680447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.